A positive benzodiazepine drug test most often reflects actual use of a prescribed or illicit benzodiazepine, but several other substances can trigger the same result. Certain prescription medications, including the anti-HIV drug efavirenz and the anti-inflammatory oxaprozin, are well-documented causes of false positives on standard screening tests. So-called designer benzodiazepines, which are not approved by the FDA but circulate online and on the street, can also set off the test. And the screening technology itself introduces complications: immunoassay-based drug screens are designed to cast a wide net, which means they sometimes react to molecules that merely resemble benzodiazepines.
Prescribed Benzodiazepines Are the Most Common Cause
The straightforward explanation is the most common one. If you take alprazolam, diazepam, clonazepam, lorazepam, or any other prescribed benzodiazepine, your urine test will usually come back positive. Your body breaks these drugs down into metabolites that the test’s antibodies are designed to recognize. After your liver processes the drug, only trace amounts of the original compound end up in your urine; most of what appears is in the form of metabolites that have been chemically tagged for excretion.1Journal of Analytical Toxicology. Rapid Enzymatic Hydrolysis Using a Novel Recombinant β-Glucuronidase in Benzodiazepine Urinalysis
That said, not every prescribed benzodiazepine triggers a positive screen with equal reliability. Lorazepam, oxazepam, and temazepam are metabolized in a way that produces compounds the standard screening antibodies react to poorly. These drugs skip the first phase of liver metabolism and go directly to a process called glucuronidation, which attaches a sugar molecule to the drug. The resulting metabolites look different enough from what the test expects that they often slip through undetected, producing a false negative rather than a positive.2The Journal of Applied Laboratory Medicine. Evaluation of a Benzodiazepine Immunoassay for Urine Drug Testing in Clinical Specimens This matters if you are taking one of these medications and your provider needs to confirm you are using it as prescribed: the test might say you are not, even though you are.
Prescription Medications That Trigger False Positives
A handful of non-benzodiazepine prescription drugs are known to cross-react with benzodiazepine immunoassays, producing a positive screen in someone who has never taken a benzodiazepine. The most striking example is efavirenz, an antiretroviral drug used to treat HIV. In a study of 100 HIV-positive patients, 49 out of 50 who were taking efavirenz tested positive for benzodiazepines on at least one screening test, compared with just 1 out of 50 patients not taking the drug. The culprit is a metabolite called 8-hydroxy-efavirenz, which the test’s antibodies mistake for a benzodiazepine.3PubMed. Efavirenz treatment and false-positive results in benzodiazepine screening tests
Oxaprozin, a nonsteroidal anti-inflammatory drug prescribed for arthritis, is another well-known offender. In a controlled study, all 36 urine specimens collected from 12 people taking oxaprozin tested positive for benzodiazepines on multiple screening platforms.4PubMed. Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine The concentrations at which oxaprozin triggered a positive result were far above the cutoff the tests use, meaning this was not a borderline interference: the tests were confidently wrong.
Sertraline, an antidepressant in the SSRI class (sold as Zoloft), has also been shown to cause false positives on older versions of benzodiazepine screening assays. The cross-reactivity was traced to specific sertraline metabolites. Newer formulations of the affected assay were redesigned to eliminate this problem, but some older assay versions may still be in use at smaller or lower-volume labs.5Journal of Analytical Toxicology. Improved CEDIA® Benzodiazepine Assay Eliminates Sertraline Crossreactivity
If you are taking any of these medications and face a drug test, mention them to your provider or the testing facility beforehand. A confirmatory test can distinguish a real benzodiazepine from a cross-reacting medication, but the screening result itself will still come back positive.
Designer Benzodiazepines
Over the past decade, a growing number of unregulated benzodiazepine-like compounds have entered the illicit drug supply. These so-called designer benzodiazepines are synthesized to mimic the effects of FDA-approved versions but are not included in standard confirmatory testing panels. They go by names like flubromazolam, flualprazolam, etizolam, and clonazolam, and they are increasingly found in counterfeit pills sold as Xanax or Valium.
Standard immunoassay screens generally do detect these compounds. A study examining 13 designer benzodiazepines found that most showed high cross-reactivity across four major commercial screening platforms.6PubMed. Detectability of designer benzodiazepines in CEDIA, EMIT II Plus, HEIA, and KIMS II immunochemical screening assays The problem comes at the next step. When a screening test flags benzodiazepines, labs typically run a confirmatory test looking for a set list of known compounds. If the lab’s confirmation panel only includes the 15 or 20 FDA-approved benzodiazepines and their metabolites, it will not find the designer compound responsible for the positive screen. The result looks like a false positive when it is actually a true positive for a substance the confirmation test was not designed to identify.
One study examined 35 emergency department urine specimens that had screened positive for benzodiazepines but came back negative on a standard 19-compound confirmatory panel. Using more advanced analysis, researchers found at least one designer benzodiazepine in 30 of those 35 specimens. Flubromazolam, flualprazolam, and etizolam were the most frequently identified, and more than a third of the specimens contained two or three designer compounds simultaneously.7PubMed. Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS and LC-MS-MS This gap between screening and confirmation is a real clinical and forensic issue: people using dangerous unregulated substances may be told their test was a false alarm.
Why Screening Tests Get It Wrong in Both Directions
Immunoassay screening tests work by using antibodies that bind to benzodiazepines or their metabolites. When enough binding occurs, the test registers as positive. This approach is fast and relatively inexpensive, which is why it is the default for workplace testing, emergency departments, and pain management clinics. But the antibodies are not perfectly selective. They are tuned to recognize structural features shared by the benzodiazepine class, and any molecule with a similar enough shape can trigger the same reaction.
This is why false positives happen: a molecule from efavirenz or oxaprozin fits into the antibody’s binding site well enough to register. It is also why different assay brands produce different results. A comparison of screening platforms used across 178 Italian forensic laboratories found that all immunoassay types had notable false-positive rates, with some platforms performing worse than others. The study’s authors warned against relying on screening results alone for forensic or legal decisions.8Journal of Analytical Toxicology. Comparison of Immunoassay Screening Tests and LC–MS-MS for Urine Detection of Benzodiazepines and Their Metabolites: Results of a National Proficiency Test
False negatives are equally common and arguably more problematic in clinical settings. As mentioned earlier, certain benzodiazepines produce glucuronidated metabolites that the standard antibodies do not recognize well. One study found that a benzodiazepine screening assay missed nearly half of confirmed-positive specimens when using the manufacturer’s default cutoff. By lowering the threshold at which samples were sent for confirmatory testing, the false-negative rate dropped from about 47% to 2%.9The Journal of Applied Laboratory Medicine. Improved Clinical Sensitivity of a Reflexive Algorithm to Minimize False-Negative Test Results by a Urine Benzodiazepine Immunoassay Screen Some laboratories have addressed this by adding an enzymatic step that breaks apart the glucuronide bond before the sample is screened, which substantially improves detection. Labs using this approach have achieved sensitivity as high as 100% for benzodiazepine-positive specimens.2The Journal of Applied Laboratory Medicine. Evaluation of a Benzodiazepine Immunoassay for Urine Drug Testing in Clinical Specimens
The bottom line is that not all labs process your sample the same way, and the assay brand, the cutoff threshold, and the sample preparation steps all affect whether the test reports a positive. Two people taking the same benzodiazepine at the same dose can get different screening results depending on the laboratory.
Confirmatory Testing and What It Can and Cannot Resolve
Any positive immunoassay screen should be followed by confirmatory testing, typically using gas chromatography-mass spectrometry (GC-MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS). These methods identify specific molecules rather than relying on antibody binding, so they can distinguish a real benzodiazepine from a cross-reacting medication. A comprehensive review of false-positive interference studies published between 2013 and 2024 reinforced that immunoassay results remain presumptive and should always be confirmed using one of these techniques before clinical or legal decisions are made.10Journal of Analytical Toxicology. False positive urine drug screens
Confirmatory testing resolves most false-positive scenarios cleanly. If your screen was triggered by efavirenz or oxaprozin, the confirmation will show no benzodiazepines. If you are taking a prescribed benzodiazepine, confirmation will identify which one. Where confirmation hits its limit is with designer benzodiazepines. Standard confirmatory panels look for a finite list of compounds. If the substance triggering the screen is not on that list, the confirmation comes back negative, and the screening result may be dismissed as a false positive even when the person genuinely ingested a benzodiazepine-like substance.7PubMed. Urine Drug Screening in the Era of Designer Benzodiazepines: Comparison of Three Immunoassay Platforms, LC-QTOF-MS and LC-MS-MS Laboratories that see frequent mismatches between screening and confirmatory results are increasingly adding broader analytical methods that can detect unknown compounds, but this capability is far from universal.
Point-of-Care Tests and Rapid Screening
Many drug tests are not run in a full laboratory at all. Emergency departments, probation offices, and some workplaces use rapid point-of-care devices that produce results in minutes. These are immunoassay-based, like laboratory screens, but tend to be less sensitive. One comparative study evaluating three point-of-care devices in an emergency department found that sensitivity for benzodiazepines ranged from 80% to around 93%, depending on the brand.11The Journal of Emergency Medicine. Evaluation of Three Point-of-Care Urine Drug-Screening Devices in the Emergency Department: A Comparative Study That means one in five benzodiazepine-positive samples could be missed by the least sensitive device. At the same time, these rapid tests are subject to the same cross-reactivity issues as laboratory immunoassays, so the same medications that cause false positives in the lab can cause them at the point of care.
If a rapid test produces a positive benzodiazepine result that you believe is incorrect, you have the right to request laboratory-based confirmatory testing. In employment and legal settings, confirmatory testing is typically required before any action is taken. In emergency medicine, a positive rapid screen may influence treatment decisions before confirmation arrives, which is one reason clinicians are trained to interpret these results cautiously.
How Long Benzodiazepines Remain Detectable
Detection windows vary enormously depending on the specific drug, the dose, how long you have been taking it, and your individual metabolism. Short-acting benzodiazepines like alprazolam can drop below detectable levels in urine within a day or two after a single dose. Longer-acting compounds like diazepam produce metabolites that linger for much longer. Diazepam’s glucuronide metabolites, for instance, remain detectable in urine well after the parent drug and its primary breakdown products have cleared.12PubMed. Extending the detection window of diazepam by directly analyzing its glucuronide metabolites in human urine using liquid chromatography-tandem mass spectrometry
Chronic use complicates things further. When you take a benzodiazepine repeatedly, the drug accumulates in fatty tissue and releases slowly over time, extending the window during which a test can detect it. Age, liver function, body composition, and genetic differences in liver enzymes all influence how quickly your body clears the drug.13Frontiers in Toxicology. Forensic toxicology of benzodiazepines: neuropharmacological effects, analytical challenges, and emerging detection strategies Two people taking the same dose on the same schedule can have meaningfully different detection windows. This variability means that general rules of thumb about how long a benzodiazepine “stays in your system” are rough guides at best.
When a Positive Result Does Not Match What You Expected
If you receive a positive benzodiazepine screen and you have not knowingly taken one, the first step is to review your medication list carefully. Efavirenz and oxaprozin are the best-documented cross-reactors, but older assay platforms have occasionally flagged other substances as well. Provide a complete medication list, including over-the-counter drugs and supplements, to whoever is interpreting the result.
If you are taking a prescribed benzodiazepine but tested negative, the issue may be the test’s inability to detect glucuronidated metabolites. This is especially common with lorazepam and oxazepam. Not every lab uses the enzymatic hydrolysis step that improves detection of these drugs, and some labs operate with cutoff thresholds that miss specimens with lower drug concentrations. During one laboratory validation, four lorazepam-positive specimens produced screening values that fell just barely below the positive cutoff, all because the effective concentration after adjusting for cross-reactivity landed beneath the assay’s threshold.14PubMed Central. Comparison of two highly sensitive benzodiazepine immunoassay lab developed tests for urine drug testing in clinical specimens
In either scenario, confirmatory testing by mass spectrometry is the definitive step. If the stakes matter, whether for employment, legal proceedings, or clinical care, do not accept a screening result as the final word. The technology is built to flag possible positives quickly and cheaply, not to provide certainty. That second step exists for a reason, and both false positives and false negatives are common enough that relying on the screen alone is, as one group of researchers put it, a practice of “great severity” in forensic contexts.8Journal of Analytical Toxicology. Comparison of Immunoassay Screening Tests and LC–MS-MS for Urine Detection of Benzodiazepines and Their Metabolites: Results of a National Proficiency Test